We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Liquid Biopsy Predicts Immunotherapy Response and Toxicity in Advanced Lung Cancer Patients

By LabMedica International staff writers
Posted on 13 Dec 2023
Print article
Image: Liquid biopsy to study genetic material shed into bloodstream helps predict response to immunotherapy (Photo courtesy of Valsamo `Elsa` Anagnostou using DALL-E)
Image: Liquid biopsy to study genetic material shed into bloodstream helps predict response to immunotherapy (Photo courtesy of Valsamo `Elsa` Anagnostou using DALL-E)

Immunotherapy has been a game-changer in treating lung cancer patients, yet assessing its effectiveness remains a challenge. The absence of reliable biomarkers means reliance on imaging and patient symptoms to gauge clinical responses. Now, new noninvasive tests offer clinicians a way to evaluate treatment responses and foresee potential side effects at an early stage, allowing for timely adjustments in therapeutic approaches.

Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) have explored the use of a "liquid biopsy" to analyze genetic material from tumors that enter the bloodstream along with immune cells. This approach could enable clinicians to predict which patients with advanced lung cancers are responding to immunotherapies and identify those who might experience immune-related side effects later on. In a study of 30 patients undergoing immunotherapy for metastatic non-small cell lung cancers, the team monitored changes in circulating tumor DNA (ctDNA). They found that molecular responses, indicated by the reduction of tumor genetic material in the bloodstream, were closely linked with progression-free and overall survival rates.

Additionally, the research included serial blood tests that identified an increase in T cells, the immune cells known for recognizing and attacking foreign entities on tumor cells. This was particularly evident in patients who developed immune-related adverse events, like lung tissue inflammation, up to five months before clinical symptoms appeared. This finding was corroborated in a separate group of 49 patients with advanced lung cancers. The liquid biopsy proved beneficial in understanding the clinical outcomes of patients who appeared to have stable disease on imaging.

“All of the patients who appeared to have stable disease on imaging tests had very different DNA molecular response patterns that helped predict their overall clinical outcomes,” said senior study author Valsamo “Elsa” Anagnostou, M.D., Ph.D. “This is a particular subset of patients for whom we may want to intervene, and use liquid biopsies to guide therapeutic decision-making, as ctDNA can rapidly and accurately capture the amount of cancer present.”

Related Links:
Johns Hopkins Medicine

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.